Arkin Holdings raises $270 million for new biotech fund

The new fund, which will be named Arkin Bio-Capital, intends to invest in 8-10 companies that are developing innovative medicine and plan on going public in the near future

Arkin Holdings, whose funds have $2 billion in assets under management, has raised $270 million for a new fund it has named Arkin Bio-Capital. In addition to Arkin Holdings, the fund received investments from Migdal Insurance, Phoenix, who invested in prior funds as well, in addition to new institutional investors: Harel Insurance, Menorah Insurance, More Investment House, and Leumi Partners. The fund is expected to invest in companies across the world.

 

The new fund, which will be managed by Alon Lazarus and Pini Orbach, intends to invest in 8-10 companies that are developing innovative medicine for diseases that require a clear medical intervention and plan on going public in the near future.

 

Pini Orbach and Alon Lazarus of Arkin Holdings. Photo: Courtesy

 

"Arkin Bio-Capital is being set up due to the unique experience we have gained in pharma over the years and the great success of the Arkin Bio-Ventures funds," said Mori Arkin, the founder and chairman of Arkin Holdings. "The new fund will strengthen our ability to invest in the best biotech companies in the world and will allow them to reach significant milestones and achievements. In addition, this fund will solidify our status as a leading investor in the global scene."

Related articles:

• Arkin Holdings turns focus to digital health, eyeing investments in early-stage startups
• aMoon raising new massive healthtech fund
• Navina secures $15 million Series A for AI primary care platform

 

Alon Lazarus added: "The strategy of Arkin Bio-Capital will be based on joining and leading large pre-IPO rounds of leading companies in their sectors who are capable of significantly affecting the health sector by developing innovative medicine."